|
業務類別
|
Biotechnology |
|
業務概覽
|
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipinefor the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights. |
| 公司地址
| 103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540 |
| 電話號碼
| +1 609 322-1602 |
| 傳真號碼
| +1 450 687-2272 |
| 公司網頁
| https://www.gracetx.com |
| 員工數量
| 5 |
| Dr. R. Loch Macdonald, M.D.,PhD |
Chief Medical Officer |
-- |
28/07/2026 |
| Mr. Robert J. DelAversano |
Vice President, Finance, Principal Financial Officer and Principal Accounting Officer |
-- |
28/07/2026 |
| Mr. Prashant Kohli |
Chief Executive Officer and Director |
美元 579.00K |
28/07/2026 |
| Mr. Amresh Kumar, PhD |
Vice President, Program Management |
美元 310.00K |
28/07/2026 |
|
|
| Mr. A. Brian Davis |
Independent Director |
28/07/2026 |
| Mr. Edward Neugeboren |
Independent Director |
28/07/2026 |
| Mr. Vimal Kavuru |
Chairman of the Board |
28/07/2026 |
| Dr. S. George Kottayil, PhD |
Director |
28/07/2026 |
| Mr. Prashant Kohli |
Chief Executive Officer and Director |
28/07/2026 |
|
|
|
|
